Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

Chemistry World June 12, 2014 Philli Broadwith	Merck & Co bolsters hepatitis C pipeline with Idenix acquisition US drug firm Merck & Co has agreed to buy hepatitis C specialist Idenix for $3.85 billion.
The Motley Fool October 19, 2007 Brian Lawler	Schering's Gain Is Only a Mild Headache for Vertex Schering-Plough's strong phase 2 clinical results of its hepatitis C virus drug candidate send shares of competitor Vertex down.
Chemistry World May 29, 2015 Phillip Broadwith	Achillion partners with Janssen to boost hepatitis C pipeline Janssen will invest $225 million in Achillion shares, and has promised performance milestone payments worth up to $1.1 billion, plus royalties on any sales.
Chemistry World October 30, 2013 Phillip Broadwith	Vertex to cut 370 jobs US biopharmaceutical firm Vertex is cutting 370 jobs as it faces a drop in demand for its hepatitis C drug Incivek (telaprevir).
The Motley Fool April 26, 2011 Brian Orelli	There Is Only Downside in Consensus Hepatitis C advisory panels will almost certainly recommend approval. Almost.
The Motley Fool July 7, 2011 Brian Orelli	J&J's Been Busy Johnson & Johnson announced it was hooking up with another partner, Pharmasset, to create a hepatitis C drug combo.
The Motley Fool January 24, 2008 Brian Lawler	Vertex Under the Gun Vertex announces development plans for its lead drug. Investors, take note.
Chemistry World January 11, 2012 Andrew Turley	BMS spends $2.5 billion on antiviral firm The move will stock Bristol-Myers Squibb's pipeline with antivirals, most notably INX-189, a nucleotide polymerase inhibitor which is in Phase II trials for treating hepatitis C virus infection.
The Motley Fool April 28, 2011 Brian Orelli	Victory for Victrelis Merck's hepatitis C drug moves one step closer to FDA approval.
Chemistry World August 20, 2009 Sarah Houlton	Testing times: predicting hep C response A finding by David Goldstein and his group at Duke University in the US may make it possible to predict which patients are likely to benefit from the drugs, and which will probably suffer the nasty side-effects without much chance of success.
The Motley Fool January 19, 2012 Brian Orelli	New Hep C Data Impressive, but It's Not There Yet All-oral treatment still has a ways to go.
Pharmaceutical Executive December 1, 2010 Walter Armstrong	Hepatitis C: Another Protease Revolution The launch of a new class of protease inhibitors is set to transform HCV treatment over the next decade, with kinder, gentler oral antiviral cocktails that will increase success rates from 50 percent to 75 percent.
The Motley Fool June 14, 2011 Brian Orelli	Going for Seconds in the Hepatitis C Space Fresh from the Food and Drug Administration's approval of its hepatitis C drug, Incivek, Vertex has licensed a pair of hepatitis C compounds from privately held Alios BioPharma.
The Motley Fool November 21, 2011 David Williamson	Pharmasset Acquired, Shares Jump 85% Gilead Sciences buys Pharmasset and hepatitis C drug PSI-7977.
The Motley Fool April 27, 2005 Charly Travers	Vertex's Emerging Pipeline Early-stage drugs, including one for hepatitis C, are moving forward. For Vertex investors, the phase 2 trials will be the story to watch over the next two years.
The Motley Fool May 17, 2011 Luke Timmerman	Merck, Genentech Team Up on Hepatitis C Drug Merck pulling lots of strings to grab market share against Vertex.
The Motley Fool July 27, 2011 Brian Orelli	Good Combo; Too Bad There's Competition Vertex's VX-222 helps standard of care but still requires an injected medication.
The Motley Fool October 20, 2010 Brian Orelli	What's Your Next Trick, Gilead? Just when investors had counted Gilead Sciences down for the count, it comes roaring back.
The Motley Fool March 31, 2011 Brian Orelli	Hepatitis C Drugs Heat Up The current hepatitis C drugs stink. Who's ahead in the race to find new ones?
The Motley Fool January 28, 2008 Brian Lawler	Vertex Has a Lot to Prove Vertex Pharmaceuticals announces that final results from its upcoming phase 3 trials wouldn't be ready until the middle of 2010, a far cry from the filing in 2008 that Vertex was previously forecasting.
The Motley Fool October 30, 2006 Brian Lawler	Vertex's Healthy Trial Results Shares of the pharmaceutical company were up on the release of positive clinical trial data.
The Motley Fool July 27, 2011 Alexander Crawford	Vertex Moving Closer to a Cure for Hepatitis C How do you think the treatment of hepatitis C will evolve?
The Motley Fool April 25, 2011 Luke Timmerman	Vertex, Merck Step Up to the Public Stage With Hepatitis C Drugs This Week Most analysts see Vertex's drug as best-in-class. But what does the FDA have to say about it?
The Motley Fool May 18, 2011 Brian Orelli	If You Can't Beat 'Em, Use 'Em to Beat Your New Rival Merck is supposed to be a bitter rival to Roche in the hepatitis C space. Instead, it's extending the hand of friendship.
The Motley Fool April 23, 2008 Brian Lawler	Vertex Verging on Crucial News Soon-to-arrive study results could decide the future of Vertex Pharmaceutical's lead drug telaprevir.
The Motley Fool September 8, 2010 Brian Orelli	You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win.
The Motley Fool October 31, 2011 Brian Orelli	Gunning for the Leaders Hepatitis C drugs take center stage.
Chemistry World September 23, 2014 Phillip Broadwith	Gilead licenses generic hepatitis C drug in India Gilead has granted licenses to seven generic drugmakers to produce its blockbuster hepatitis C drug Sovaldi (sofosbuvir) in India and 90 other developing nations.
The Motley Fool September 19, 2008 Brian Lawler	FDA Tells Gilead to Take 1 More Step There's a small consolation prize for Gilead Sciences in this rejection from the FDA.
The Motley Fool September 7, 2010 Luke Timmerman	Vertex Nails Third Big Trial With Hepatitis C Drug And in the toughest patients to treat, too.
Fast Company March 2015 J.J. McCorvey	How Drug Company Gilead Outpaces Its Competitors -- And Common Diseases Over the past few years, Gilead has ushered through four effective new treatments for HIV alone.
The Motley Fool September 26, 2007 Brian Orelli	Second-Line Isn't Second Best Schering-Plough gets a positive recommendation for its hepatitis C drugs as a second-line treatment in Europe.
Chemistry World October 1, 2014 Phillip Broadwith	J&J to buy antiviral specialist Alios Johnson and Johnson has agreed to buy antiviral specialist Alios BioPharma for $1.75 billion
The Motley Fool July 29, 2011 Brian Orelli	Vroom! There Goes Vertex Vertex Pharmaceuticals' Incivek launch is off to a good start.
The Motley Fool December 28, 2007 Brian Lawler	Cubist's Cheap Call Option As a Christmas Eve present to itself, Cubist Pharmaceuticals follows through on its October option to purchase Illumigen.
The Motley Fool November 6, 2007 Brian Lawler	No Surprise That Vertex Has Competition Did shares of Vertex Pharmaceuticals slump on competition concerns?
The Motley Fool December 9, 2008 Brian Orelli	Human Genome's Hep C Drug Is Halfway Home One trial down, one to go for Human Genome Sciences.
The Motley Fool August 30, 2010 Brian Orelli	Pipeline Checkup: Merck Has Potential The Schering-Plough acquisition has seemed to help.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
The Motley Fool September 7, 2007 Brian Orelli	Merck Says No to This Protein An FDA advisory panel recommends unanimous approval of a new HIV drug from Merck. The new class of HIV medications fight the virus by blocking one key protein from entering cells.
The Motley Fool August 4, 2010 Brian Orelli	No Nail Yet, but Vertex Creeps Up to Merck's Coffin Merck's hepatitis C data doesn't look as good as Vertex's.
The Motley Fool December 31, 2007 Brian Lawler	Best Stock for 2008: Gilead Sciences Shares of Gilead Sciences are a good bet for next year.
Chemistry World April 21, 2010 Sarah Houlton	Fresh hep C hope A new kind of compound to treat hepatitis C is showing promise in early clinical trials.
Chemistry World January 6, 2015 Sarah Houlton	Riding new waves Global annual spending on medicines is set to top $1 trillion for the first time in 2014, having ended 2013 just shy of that figure at $989 billion.
The Motley Fool May 23, 2008 Brian Lawler	Vertex's Lead Cut Down Schering-Plough is moving forward with its antiviral hepatitis C drug even faster than expected, much to Vertex's dismay.
The Motley Fool July 25, 2007 Brian Lawler	Vertex Is on Its Way Vertex Pharmaceuticals is still years away from any regulatory approval on telaprevir in the U.S., but highlights promising results so far in its quarterly report.
The Motley Fool April 3, 2008 Brian Lawler	Will InterMune's Hepatitis C Drug Compete? InterMune announces positive data for its hepatitis C treatment drug.
The Motley Fool January 30, 2009 Brian Orelli	Mark Your Calendars: The Race Is On! In the last couple of weeks, both Schering-Plough and Vertex Pharmaceuticals have announced that their phase 3 hepatitis C drugs trials have finished enrolling patients.
The Motley Fool June 16, 2011 Brian Orelli	Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA.
The Motley Fool April 1, 2008 Brian Lawler	Vertex Proves It ... Almost Vertex announces exciting clinical trial data that could get its anti-hepatitis C virus compound onto the market years earlier.